Bogotá, Colombia – 14 April 2018
Objective is to improve access to diagnosis and treatment of people affected by this disease
An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).
Bogotá, Colombia – 14 April 2018
Paris – 12 April 2018
Results support a public health approach to hepatitis C
An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.
Osaka, Japan and Geneva, Switzerland – 5 April 2018
Efforts funded by the Global Health Innovative Technology Fund for pre-clinical and phase I clinical studies
Takeda Pharmaceutical Co., Ltd. and DNDi today announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).
24-25 May 2018
Olawale Salami, Paediatric HIV Clinical Project Manager DNDi Africa – presentation of the LIVING study on treatment for paediatric HIV
Leishmaniasis Team, DNDi – presentation on PKDL in the Indian subcontinent
Jorge Alvar, Senior Leishmaniasis Advisor, DNDi – presentation on HIV-VL in East Africa
Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
The Star Online [20 March 2018]
“NGOs laud ministry’s efforts as a win for public health”
Infobae [16 March 2018]
“Hepatitis C: la importancia de un diagnóstico a tiempo para mejorar el tratamiento de una ‘enfermedad olvidada'” – “Hepatitis C: the importance of a timely diagnosis to improve the treatment of a ‘neglected disease'”
Drug Discovery News [14 March 2018]
“Working the crowd”
Medscape [9 March 2018]
“Anuncian el desarrollo de un tratamiento accesible en Latinoamérica para la hepatitis C” – “Announcing the development of an accessible treatment in Latin America for hepatitis C”
Le Quotidien du Médecin [8 March 2018]
“Hépatite C: le sofosbuvir ‘low cost’ du DNDi arrive en Amérique du Sud” – “Hepatitis C: DNDi’s ‘low cost’ sofosbuvir arrives in South America”
BioCentury [7 March 2018]
“DNDi, partners aim to bring cheaper HCV combo to Latin America”
Buenos Aires/Ginebra – Marzo de 2018
Una nueva colaboración entre compañías farmacéuticas y organizaciones sin fines de lucro permitirá producir y suministrar un nuevo régimen de tratamiento de la hepatitis C, a precios más accesibles para la población en América Latina. Se estima que 3,5 millones de personas viven con esta enfermedad viral en la región, y aproximadamente 325.000 en Argentina. El alto precio de los tratamientos constituye una de las muchas barreras para acceder a una atención adecuada.
Buenos Aires, Geneva – 5 March 2018
A new collaboration between pharmaceutical companies and non-profit organizations will manufacture and supply a new, more affordable, hepatitis C treatment regimen in Latin America. An estimated 3.5 million people live with this viral disease in Latin America including around 325,000 in Argentina, with high treatment prices one of the many barriers to access for life-saving care.